Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGNYTE-ESO: Letetresgene autoleucel in NY-ESO-1+ Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
NCT03967223Phase 2Active, not recruiting
- Sponsor
- US WorldMeds
- Start
- Dec 2019
- Primary completion
- Mar 2024
- Modality
- CAR-T Cells
- Countries
- 7
01
Overview
Phase 2, open-label trial of letetresgene autoleucel in synovial sarcoma (SS) and myxoid round cell liposarcoma (MRCLPS) (2 arms), sponsored by US WorldMeds. Primary endpoint: Overall Response Rate up to 5 years. Started Dec 2019; status: active, not recruiting.
02
Drugs
letetresgene autoleucel
03
Conditions
synovial sarcoma (SS)myxoid round cell liposarcoma (MRCLPS)
Beyond the preview
Go deeper on NCT03967223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03967223.